Niagen Bioscience (NASDAQ:NAGE) Stock Price Target Cut by Freedom Broker

by · The Markets Daily

Niagen Bioscience (NASDAQ:NAGE – Get Free Report) had its price objective reduced by Freedom Broker from $8.50 to $6.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Freedom Broker‘s price target would indicate a potential upside of 189.86% from the company’s previous close.

NAGE has been the topic of several other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, October 15th. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group lowered their price objective on Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $8.50.

View Our Latest Research Report on Niagen Bioscience

Niagen Bioscience Trading Down 1.9%

NAGE stock traded down $0.04 during trading on Friday, reaching $2.07. 597,674 shares of the stock were exchanged, compared to its average volume of 839,384. The stock has a 50 day simple moving average of $2.79 and a 200-day simple moving average of $3.85. Niagen Bioscience has a twelve month low of $2.04 and a twelve month high of $7.28. The company has a market capitalization of $164.85 million, a P/E ratio of 17.25 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.26%. The firm had revenue of $27.19 million during the quarter. Equities analysts predict that Niagen Bioscience will post 0.08 EPS for the current year.

Institutional Trading of Niagen Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Stoneridge Investment Partners LLC acquired a new stake in Niagen Bioscience in the 2nd quarter worth approximately $49,000. Kestra Advisory Services LLC raised its stake in shares of Niagen Bioscience by 81.5% in the third quarter. Kestra Advisory Services LLC now owns 24,500 shares of the company’s stock valued at $72,000 after acquiring an additional 11,000 shares in the last quarter. Teton Advisors LLC lifted its position in shares of Niagen Bioscience by 20.0% during the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock worth $132,000 after buying an additional 5,000 shares during the last quarter. Abel Hall LLC acquired a new position in Niagen Bioscience in the 3rd quarter valued at about $99,000. Finally, Chicago Partners Investment Group LLC purchased a new position in shares of Niagen Bioscience in the 1st quarter valued at about $214,000. Institutional investors own 15.41% of the company’s stock.

Trending Headlines about Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

  • Positive Sentiment: Management highlighted positive cash flow on its Q3 earnings call, while the company outlined plans for a 5,000-participant, three-year Mass General Brigham trial and is targeting early-2027 commercialization of NR malate. These developments could support longer-term growth, though execution and commercialization remain ahead. Q3 2026 earnings call highlights Trial and commercialization plans
  • Neutral Sentiment: Canaccord Genuity lowered its price target to $7 from $9 but maintained a Buy rating. The reduced target is a setback, while the continued Buy rating signals the analyst still sees substantial potential from the referenced $2.07 share price. Canaccord price-target update
  • Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 estimates to losses of $0.02 per share each, and reduced its full-year 2026 and 2027 EPS forecasts to $0.05 from $0.14. It also lowered estimates across 2027 quarters, indicating weaker expected profitability. Analyst estimate updates
  • Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, in line with expectations but down from earnings of $0.05 a year earlier; revenue also missed estimates, adding to near-term concerns. Q3 results

Niagen Bioscience Company Profile

(Get Free Report)

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.

Further Reading